Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Overview of attention for article published in Journal of Clinical Oncology, May 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 44 news outlets
blogs: 16 blogs
policy: 1 policy source
twitter: 98 X users
patent: 93 patents
facebook: 13 Facebook pages

wikipedia: 10 Wikipedia pages
googleplus: 4 Google+ users
reddit: 8 Redditors
f1000: 1 research highlight platform
guideline: 8 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 1571 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 18 posts from 16 blogs.

Os vírus que combatem o câncer: uma nova esperança na terapia

Cientistas descobriram que… "CDQ", 28 Aug 2024

Izabella Thaís da Silva – Departamento de Ciências Farmacêuticas – Universidade Federal de Santa Catarina (UFSC) Você já ouviu…

Onkolitik Virüs Nedir? Kanser Tedavisinde Virüsler Kullanılabilir!

Evrim Ağacı, 31 May 2023

Kanser hücresine saldıran onkolitik virüs. Kaynak…

T-VEC becomes first viral immunotherapy approved in Europe

Institute of Cancer Research, 18 Dec 2015

A viral immunotherapy for cancer has become the first of its kind to be approved by the European Medicines Agency for use in…

Highlights of the year, 2015

Institute of Cancer Research, 07 Dec 2015

We look back at our researchers' scientific achievements to pick out ten of our most exciting discoveries from the past year.

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 14 additional blog posts.